OSLO (Reuters) – Novo Nordisk’s widely used diabetes drug Ozempic delayed progression of chronic kidney disease in diabetes patients, according to a large late-stage study.
“The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in kidney disease progression, major adverse cardiovascular events (MACE) and death of 24%,” it said in a statement.
(Reporting by Stine Jacobsen and Maggie Fick; Editing by Josephine Mason and Terje Solsvik)
Comments